availability has been significantly curtailed - No branded pharmaceutical product exists **Semaglutide:** - FDA-approved for weight management (Wegovy, 2.4 mg weekly) - FDA-approved for type 2 diabetes (Ozempic, up to 2.0 mg weekly) - Available through licensed pharmacies worldwide - Also available through 503B compounding pharmacies as a **weight loss peptide injection** - [View semaglutide products](/products/semaglutide-001) ### Injection Protocol Comparison **AOD-9604 typical research protocol:** - Dose: 250-300 mcg per injection - Frequency: Daily subcutaneous injection (fasting, typically morning) - Cycle length: 12-20 weeks - Total injections per month: ~30 **Semaglutide weight loss injection protocol:** - Starting dose: 0.25 mg weekly (4-week titration steps) - Maintenance dose: 2.4 mg weekly - Frequency: Once weekly subcutaneous injection - Total injections per month: 4 The convenience advantage is substantial

It means products stored in temperature-controlled Canadian facilities rather than sitting in shipping containers during cross-border transit
(There is a method, advocated by some US doctors, in which phenobarbitone, a long-acting barbiturate, is substituted for a benzodiazepine and then slowly withdrawn, but this method has no particular advantages over tapering directly from a long-acting benzodiazepine)
Multiply the mL value by 100 to get units
BPC-157 is commonly used daily for 4-8 week cycles based on preclinical safety data showing no adverse effects at therapeutic doses
Proper handling, using sterile needles, and limiting unnecessary opening of the vial can help reduce this risk